DOCSLIB.ORG

STEMCELLNETWORK.CA the Mission of the Stem Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
STEMCELLNETWORK.CA the Mission of the Stem Cell STEM CELL NETWORK SUMMER 2006 VOLUME 5, NUMBER 1 FATHERS OF THE FIELD How two quiet Canadians changed the course of history in biological research. CRITICAL MASS AHEAD OF THE CURVE A CANADIAN A pioneering past and a culture of Finding the way inside the ‘black box’ COMES HOME collaboration combine to make Toronto of cancer, Dr. John Dick has changed One of America’s leading researchers a world leader in stem cell science. our understanding of how to fight takes up a new challenge in the city the deadly disease. where he began his brilliant career. WWW.STEMCELLNETWORK.CA The mission of the Stem Cell Network is to be a catalyst for realizing the full potential of stem cell research for Canadians. STEM CELL NETWORK Frank Gleeson, Chair, Board of Directors Dr. Michael Rudnicki, Scientific Director Dr. Janet Rossant, Deputy Scientific Director Drew Lyall, Executive Director Cathy Campbell, SCN Communications Lori Barron, SCN Communications Joe Sornberger, Writer CONTACT US AT: 451 Smyth Road, Ottawa, ON K1H 8M5 Tel: (613)562.5696 Fax: (613)562.5631 Website: www.stemcellnetwork.ca Publication Mail Agreement Number 40664504 The contents of this publication may be reprinted or used in radio or television without permission. However, a credit is requested. In print, please send a copy to the Stem Cell Network. STEM CELL NETWORK TABLE OF CONTENTS Welcome to Toronto - Dr. Michael Rudnicki .......................................1 Critical Mass .................................................................................2 The Fathers of the Field .................................................................8 A Canadian comes home - Interview with Dr. Gordon Keller ...............14 The world’s best feel right at home ..............................................15 On the Cover: Ahead of the curve - Interview with Dr. John Dick .............................17 ”Fathers of the Field” Why I work in Canada - Interview with Dr. Mike Bhatia ....................19 Dr. James Edgar Till and Dr. Ernest Armstrong Business is good...........................................................................20 McCulloch have forever changed the course of Pull-out Map of Toronto...............................................................23 scientific research in the field of biology Cover photo credit: Critical Mass Lucas Oleniuk/Toronto Star Toronto is fast becoming the hub Pg.8 of stem cell research. What’s making this metropolis so attractive to the scientific communtiy? Pg.2 The world’s best feel right at home Canada’s history of achievement, coupled with attractive programs such as the Canadian Foundation for Innovation and the Canada Research Chairs initiative have made the country a magnet for the world’s best and brightest young stem cell scientists. Pg.15 Stem Cell Network two pioneers. Canadians have led advances in the understanding of adult stem cells, of neural, mus- cle, retinal and pancreatic stem cells. We have probed the cellular beginnings of leukemia and other cancers. We have done groundbreaking work in the root causes of Parkinson’s and degenerative muscular diseases. And we are looking deeply at cardiovascular disease and stroke and applying our stem cell expertise there. This is remarkable because while Canada is a big country, we do not have a big population. While many of our top stem cell scientists WELCOME TO work closely together in Toronto, many more are spread across the breadth of the country, TORONTO co-operating on outstanding projects in Halifax, Montreal, Ottawa, Hamilton, Calgary, Edmonton, Vancouver and Victoria. This is possible because the culture of collaboration Dr. Michael Rudnicki, Scientific Director, that was initiated by Drs. Till and McCulloch Stem Cell Network and nurtured by those who followed was formalized with the creation of the Stem Cell n behalf of the Stem Cell Network, I am Network. We have succeeded in defeating Odelighted to welcome the members of the geography by bringing together leading thinkers International Society for Stem Cell Research in different locations and different disciplines to Toronto. to find ways to fight diseases that have baffled science for too long. It only seems fitting that the ISSCR’s first conference outside of the United States should But the science of stem cells transcends all be here in Canada. As the pages of this special borders.The ISSCR and this conference stand edition of our newsmagazine show, this is as proof of that. Stem cell science remains, where it all began – thanks to the pioneering in many ways, an emerging field that brings work of Drs. James Till and Ernest McCulloch. together investigators working in many diverse More than 40 years ago, they proved the exis- areas. Consequently, the sharing of knowledge tence of stem cells and launched a whole new and information is critically important towards field of scientific endeavour. advancing our field. We are delighted to have delegates from around the world visit Toronto, We are very proud, too, of the fine work that has and look forward to what promises to be an been carried on by “the descendants” of those unrivalled ISSCR conference. ❧ Page 1 Stem Cell Network STEM CELL NETWORK By Joe Sornberger y now, the story is legend. It is also true. On a CRITICAL MASS BSunday afternoon in 1960, Dr. Ernest ‘Bun’ McCulloch dropped in at his old Ontario Cancer There’s something unique about Toronto. Institute (OCI) lab to collect some specimens. He noticed that “bumps” on mice spleens correspond- There’s the history, of course. The ed with the bone marrow cell doses given to the ani- mals.The next day, he showed the results to his bio- pioneering work done at the Ontario physicist partner,Dr.James Edgar Till, and they set Cancer Institute by Drs. James Till and to work, calling call the bumps “spleen colonies.” By 1963, they had published a definitive paper in Ernest McCulloch proved the existence Nature that showed the colonies were created by single cells with “multipotent” properties. Stem of stem cells. But it’s more than that. cell science had begun. The spirit of collaboration they instilled Largely unheralded for years, their remarkable has carried forward, so that four decades achievement was recognized last year with the Lasker Award, North America’s highest honour for later it is stronger than ever.It has made medical science research. Drs. Till and McCulloch, however, did much more than just start the science Toronto – and Canada – one of the best of stem cells.They established an ethos.They created places in the world for stem cell science. a culture of collaboration that, more than 45 years later,has kept Toronto and Canada at the forefront of stem cell research. “It’s interesting, how an ethos develops in an insti- tution and how that can permeate in the long term,” says Dr. John Dick, a Canada Research Chair and Director of the Stem Cell Biology Program at Toronto General Research Institute, which is part of Toronto’s University Health Network. “I would argue that it was really the way that science was done, the principles of the scientific process that people like James Till, Ernest McCulloch, Lou Siminovitch and some of the other leaders in Toronto practised at that time.They did science in its purity and with openness. They imbued that in their trainees, so that we’re now living by the principles that they set down 40 years ago in terms of how we operate and how we function.” Stem Cell Network Page 2 It’s exciting to be part of it.There is so much going on, intellectually. People are now centralized instead Phillips, President and CEO Ontario Cancer of being scattered all over. New Research Network, have recruited and men- tored a brilliant collection of stem cell scien- people are coming in and new money tists. More importantly, they’ve nurtured that is being poured in from donors. It’s original culture of collaboration. great. It’s the classic thing of being “People would rather collaborate than com- pete,” says Dr. Dick, who counts Drs. Bernstein in the right place at the right time. and Phillips as his mentors. “That creates a very open atmosphere. It means students can Dr. Freda Miller, Senior Scientist, SickKids Hospital easily move from one lab to another.They can get information – nobody’s holding on to infor- mation tightly because they’re worried that someone’s going to scoop their latest data. When you can talk about your latest idea before you’ve done any experiments, that cre- ates a legacy that is enormous. Of course, the Stem Cell Network is a part of that. But I think it’s also something unique about Toronto.” Certainly Toronto has the critical mass for collaboration.Within a five-minute walk of the University of Toronto are four major teaching hospitals (Princess Margaret, Mount Sinai, SickKids and Toronto General), each with affiliated research institutes that are all very large and very active. Dr. Freda Miller Dr. Janet Rossant, Chief of Research at The people who worked with or trained under SickKids and an internationally recognized Drs. Till and McCulloch and Siminovitch, the expert in developmental biology and stem latter a pioneer in the study of genetics in cells, says that ethos of collaboration in Canada, have gone on to do seminal work in Toronto, and across Canada, “really enhances the field of stem cell science. People like Dr. our ability to have an impact. Alan Bernstein, who was supervised by Dr.Till at OCI and who now is President of the “I like to think about the issues around cancer Ottawa-headquartered Canadian Institutes of stem cells,” says Dr.Rossant, who was recruit- Health Research (CIHR), Dr. Ron Worton, ed to come to Toronto by Dr. Bernstein. “John founder and first scientific director of the Dick, of course was the person to really iden- Canada-wide Stem Cell Network, and Dr. Bob tify that leukemias, blood-borne cancers, have Page 3 Stem Cell Network STEM CELL NETWORK stem cells that really are the ‘bad guys’ in the cancer.
Load more

Recommended publications
  • AIRE Is a Critical Spindle-Associated Protein in Embryonic Stem Cells Bin Gu1, Jean-Philippe Lambert2, Katie Cockburn1, Anne-Claude Gingras2,3, Janet Rossant1,3*
    RESEARCH ARTICLE AIRE is a critical spindle-associated protein in embryonic stem cells Bin Gu1, Jean-Philippe Lambert2, Katie Cockburn1, Anne-Claude Gingras2,3, Janet Rossant1,3* 1Program in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, Canada; 2Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Toronto, Canada; 3Department of Molecular Genetics, University of Toronto, Toronto, Canada Abstract Embryonic stem (ES) cells go though embryo-like cell cycles regulated by specialized molecular mechanisms. However, it is not known whether there are ES cell-specific mechanisms regulating mitotic fidelity. Here we showed that Autoimmune Regulator (Aire), a transcription coordinator involved in immune tolerance processes, is a critical spindle-associated protein in mouse ES(mES) cells. BioID analysis showed that AIRE associates with spindle-associated proteins in mES cells. Loss of function analysis revealed that Aire was important for centrosome number regulation and spindle pole integrity specifically in mES cells. We also identified the c-terminal LESLL motif as a critical motif for AIRE’s mitotic function. Combined maternal and zygotic knockout further revealed Aire’s critical functions for spindle assembly in preimplantation embryos. These results uncovered a previously unappreciated function for Aire and provide new insights into the biology of stem cell proliferation and potential new angles to understand fertility defects in humans carrying Aire mutations. DOI: 10.7554/eLife.28131.001 *For correspondence: janet. [email protected] Introduction Competing interests: The Self-renewal capability, defined as the ability of cells to proliferate while sustaining differentiation authors declare that no potential, is one of the defining features of stem cells (Martello and Smith, 2014).
    [Show full text]
  • Universidad Autónoma De Madrid
    UNIVERSIDAD AUTÓNOMA DE MADRID DEPARTAMENTO DE BIOLOGÍA MOLECULAR Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Madrid, 2015 DEPARTAMENTO DE BIOLOGÍA MOLECULAR FACULTAD DE CIENCIAS UNIVERSIDAD AUTÓNOMA DE MADRID Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Licenciatura en Biología Molecular y Fisiología Director de Tesis: Prof. Christopher Heeschen, M.D. PhD Centro de células madre en el cáncer y el envejecimiento Barts Instituto de Cancer (BCI) This thesis, submitted for the degree of Doctor of Philosophy at the Universidad Autónoma de Madrid, has been completed in the Stem Cells & Cancer Group at the Spanish National Cancer Research Centre (CNIO) and Centre for Stem Cells in Cancer and Ageing, Barts Cancer Instutute (BCI) under the supervision of Prof. Dr. Christopher Heeschen. Dedicated to my parents, my sister Ivana and my friends who always supported me. ACKNOWLEDGEMENTS It is strange to look back in time and see myself entering true the door of CNIO my first day in Christopher’s laboratory back in October 2010. For some maybe little and for other’s so much. Thank you Christopher for replaying to my email and opening me the door of your lab! It was just a start of an incredible journey that led me where I am now, and that will mark my next trails to run. So many people I need to mention and say thanks for their unconditional help and support. Enza thank you for accepting me as your student and for being patient with me. I will never forget how you would always tell me to think why I am doing things.
    [Show full text]
  • 2015 Annual Report
    1 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................. 2 HISTORY OF THE GAIRDNER FOUNDATION .................................................................................... 3 MISSION ...................................................................................................................................................... 3 NATIONAL AND STUDENT OUTREACH PROGRAMS ....................................................................... 4 MESSAGE FROM THE CHAIR ............................................................................................................... 5 MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR ......................................................... 6 2015 YEAR IN REVIEW ............................................................................................................................. 7 REPORT ON 2015 OBJECTIVES ............................................................................................................ 14 THE YEAR AHEAD: OBJECTIVES FOR 2016 ..................................................................................... 16 THE GAIRDNER FOUNDATION VALUES OUR 2015 SPONSORS ................................................... 18 GOVERNANCE ......................................................................................................................................... 20 MEDICAL REVIEW PANEL 2015 .........................................................................................................
    [Show full text]
  • University of Toronto University-Wide Impact Presentation
    UNIVERSITY OF TORONTO UNIVERSITY-WIDE IMPACT PRESENTATION INTRO: .......................................................................................... 2 SECTION 1: GLOBAL FOOTPRINT .............................................. 3 SECTION 2: INNOVATION AND IMPACT .................................... 15 SECTION 3: EXCELLENCE AND LEADERSHIP IN SOCIETY ..... 31 Text is not editable on animation slides. Updated May 2021 ON-SCREEN IMAGE SPEAKER’S NOTES BEGINNING OF PRESENTATION [Good afternoon]. My name is [X], and I serve as [X] at the University of Toronto. Thank you for joining us [today]. [Today] I would like to take you through a presentation that speaks to the crucial role that U of T is honoured to play in our communities and our world. U of T is a world-leading university with three campuses in the Greater Toronto Area. We provide students with a comprehensive global education, produce life-changing research, and promote economic growth and social progress in our communities. I’m going to cover three aspects: • U of T’s Global Footprint • U of T’s Innovation and Impact • U of T’s Excellence and Leadership in Society Since its very early days, U of T has been fortunate to have forged connections with institutions around the world and to have welcomed faculty and students from elsewhere to become part of the U of T community. Today, U of T’s global footprint is significant. 2 SECTION 1 GLOBAL FOOTPRINT 3 ON-SCREEN IMAGE SPEAKER’S NOTES We are immensely proud of our worldwide alumni community. Over 630,000 U of T alumni live, work and contribute to civil society in more than 190 countries and territories. Few universities in the world can rival the cultural diversity of our student population.
    [Show full text]
  • Beacon in Developmental Biology
    NEWS Beacon in developmental biology n Cite as: CMAJ 2017 October 16;189:E1298-9. doi: 10.1503/cmaj.109-5460 Posted on cmajnews.com on September 27, 2017. he identification of Gurdon, whom some people the genes responsi- may know recently received ble for controlling the Nobel Prize for his work Tcellular fate and embryonic cloning frogs; undertaking development in mice has research that demonstrates made Dr. Janet Rossant a that all of development is beacon in the field of written in our genes, and all developmental biology. of our cells contain DNA that Her work pioneered tech- has that information, yet niques that allowed genes somehow during develop- to be altered within ment, different genes are embryos. It also acceler- turned on and differentiation ated avenues in the fields occurs. That’s what really of stem cell biology and turned me on to the underly- regenerative medicine. ing problem of ‘how do we She was awarded the get from a fertilized egg to an 2015 Canada Gairdner organism?’ John is the per- Wightman Award, pre- son who really turned me on sented annually to a Cana- to that question and he has dian who has demon- been pursuing it ever since strated outstanding and so have I.” leadership in medicine and medical science. Rossant For the diverse audience was recognized “for her who read CMAJ, can you outstanding contributions explain what stem cells to developmental biology are? and for her exceptional “Stem cells are cells that international leadership in have the ability to self- stem cell biology and pol- renew, make endless copies icy-making, and in advanc- of themselves and yet also ing research programs for retain the potential to differ- children’s illnesses.” Courtesy of Dr.
    [Show full text]
  • Radiation Medicine Program
    Radiation Medicine Program ANNUAL 2020 REPORT 2021 VALUES MISSION Innovation Advance exemplary radiation Excellence medicine through patient Collaboration care, research & education Accountability in partnership with CONTENTS Integrity our patients & community 4 A Message from the Chief 6 Program Overview 7 2020: The Year in Numbers 8 Strategic Roadmap to 2026 VISION 10 Clinical Care CURE EVOLVE 15 Quality & Safety Predictive Health & Precision Radiation Medicine. Advanced Particle Adaptive Radiotherapy Therapy & Theranostics 18 Education Personalized Care. 21 Research Global Impact. 26 Team RMP COMFORT & CONNECT Systems to Maximize CONFIDENCE Innovation & Wellbeing Technology-enabled Patient Experience Transformation A MESSAGE FROM THE CHIEF The Radiation Medicine Program (RMP) at the Princess Margaret Cancer Centre is committed to delivering the highest standard of patient care. Over the RMP’s innovative education programs continue to thrive and attract a diverse group of national and international attendees. Our award-winning Accelerated past year, our dynamic multidisciplinary team of radiation oncologists, medical physicists, radiation therapists, administrators, and support staff have worked Education Program (AEP) demonstrated extraordinary resourcefulness this past year, standing strong amidst the pandemic, and continuing to provide top- together to advance our vision of “Precision Radiation Medicine. Personalized Care. Global Impact.” RMP continues to uphold our foundational values of level education to a broad spectrum of learners.
    [Show full text]
  • Canada Scientific Advisory Committee (CSAC)
    Canada Scientific Advisory Committee (CSAC) Alan Bernstein, PhD – Co-chairperson Canadian Institute for Advanced Research Toronto, Ontario Alan Bernstein is President of the Canadian Institute for Advanced Research (CIFAR), Canada’s global research institute. From 2008- 2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. Previously, he served as the founding president of the Canadian Institutes of Health Research (2000-2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his PhD from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974-1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto, was named Associate Director in 1988 and then Director of Research (1994-2000). Internationally known for his contributions to our understanding of the molecular basis of cancer, Bernstein has made extensive contributions to the study of stem cells, hematopoiesis and cancer. He chairs or is a member of advisory and review boards in Canada, the US, UK and Italy. Bernstein has received numerous awards and honourary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a Senior Research Fellow of Massey College, received the Order of Ontario in 2018 and was appointed an Officer of the Order of Canada in 2002.
    [Show full text]
  • Annual Report Fy 2018 Human Frontier Science Program Organization
    APRIL 2017 APRIL 2018 — MARCH 2019 ANNUAL REPORT FY 2018 HUMAN FRONTIER SCIENCE PROGRAM ORGANIZATION The Human Frontier Science Program Organization (HFSPO) is unique, supporting international collaboration to undertake innovative, risky, basic research at the frontier of the life sciences. Special emphasis is given to the support and training of independent young investigators, beginning at the postdoctoral level. The Program is implemented by an international organisation, supported financially by Australia, Canada, France, Germany, India, Italy, Japan, the Republic of Korea, New Zealand, Norway, Singapore, Switzerland, the United Kingdom of Great Britain and Nothern Ireland, the United States of America, and the European Commission. Since 1990, over 7000 researchers from more than 70 countries have been supported. Of these, 28 HFSP awardees have gone on to receive the Nobel Prize. 2 The following documents are available on the HFSP website www.hfsp.org: Joint Communiqués (Tokyo 1992, Washington 1997, Berlin 2002, Bern 2004, Ottawa 2007, Canberra 2010, Brussels 2013, London 2016): https://www.hfsp.org/about/governance/membership Statutes of the International Human Frontier Science Program Organization: https://www.hfsp.org/about/governance/hfspo-statutes Guidelines for the participation of new members in HFSPO: https://www.hfsp.org/about/governance/membership General reviews of the HFSP (1996, 2001, 2006-2007, 2010, 2018): https://www.hfsp.org/about/strategy/reviews Updated and previous lists of awards, including titles and abstracts:
    [Show full text]
  • ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science
    ANNUAL REPORT 2015/2016 Message from the Minister of Research, Innovation and Science On behalf of the Government of Ontario I am pleased to have the opportunity to extend my thanks to the Ontario Institute for Cancer Research (OICR) for another successful year in its progress to meet the cancer challenge. A report issued recently by Cancer Care Ontario tells us that one in two Ontarians will develop cancer in their lifetime and cancer is the leading cause of death in the province. We have to do everything possible to alleviate the burden of cancer on Ontario families by improving the prevention, detection, diagnosis and treatment of cancer. We are proud of our investment in OICR over the last 10 years and recently approved the Institute’s Strategic Plan for 2016-2021. OICR has demonstrated leadership in the cancer community not only in its research programs but also in its focus on moving discoveries into the clinic. An example is the development of a novel oncolytic viral immunotherapy which is now in clinical trials. Through OICR’s commercialization partner, the Fight Against Cancer Innovation Trust, financial and in-kind support are attracted which makes it possible to accelerate development and therefore bring new hope to patients. The past year has been one of accomplishment and one of transition. Dr. Calvin Stiller, who was instrumental in the creation of the Institute, has stepped down as Chair of the Board of Directors. We are most grateful for his vision and leadership. Dr. Tom Hudson, who built the Institute, attracted talented researchers and launched provincial, national and international initiatives that are helping to make Ontario a world leader in cancer research, has moved on to the next phase of his career.
    [Show full text]
  • Balancing Potency and Differentiation in Mouse Embryo-Derived Stem Cells and in Vivo
    Balancing potency and differentiation in mouse embryo-derived stem cells and in vivo By Anne Christine Helness A thesis submitted to Imperial College London for the degree of Doctor of Philosophy Department of Surgery and Oncology Imperial College London September 2011 1 Abstract An inherent challenge for developing organisms is to maintain a critical balance between cell potency and differentiation. This is most obvious in embryonic stem (ES) cells where genetic, epigenetic and cell signalling pathways support ES cell ability to self-renew and to generate all embryonic lineages. Recently, a series of reports revealed how Polycomb-mediated repression might buffer the precocious expression of somatic lineage regulators in ES cells. Notably, these genes carry bivalent chromatin enriched in both repressive (H3K27me3) and permissive (H3K4me2) histone marks. They are targeted by the Polycomb repressive complexes PRC1 (Ring1B) and PRC2, which mediates H3K27me3 and assemble poised RNA polymerase II (RNAP II), conferring silencing of loci primed for future activation (or repression) upon ES cell differentiation. During early development the transition from morula to blastocyst is the starting point for lineage segregation into the inner cell mass (ICM) and trophectoderm (TE). ES cells are derived from the ICM and are pluripotent. By contrast, TE-derived trophoblast stem (TS) cells are multipotent and contribute solely to placenta formation in vivo. To address whether ES cells epigenetic features are unique attributes of pluripotent cells in the early embryo, we compared the epigenetic status of key developmental genes in blastocyst-derived stem cells and in vivo. We provide direct evidence that bivalent histone markings operate in vivo from the eight-cell up to the blastocyst stage.
    [Show full text]
  • Princess Margaret Cancer Centre Annual Report
    2 015 A NNU A L REPORT 3 Leadership Message 4 Our Program 4 Who we are Welcome to the 2015 Annual Report for the Princess Margaret Cancer Centre at the University Health Network (UHN). This year proved to be both exciting and engaging as we continue to deliver revolutionary cancer care for our patients, and we are looking 6 Clinical Care forward to sharing the progress we have made. The 2015 edition showcases the recent 6 Our Clinical Programs LEADERSHIP activities and accomplishments of our people, departments, disease groups, and research and education programs. As one of the largest comprehensive cancer treatment facilities in the world, we have a great deal to share as we continue our efforts to be on the 8 Personalized Cancer Medicine MESSAGE frontiers of medical, surgical and radiation oncology, embracing the latest technology 8 Our Strategy and international best-practices, and setting standards for patient care. 9 We Are Transforming Patient Care In 2015, we celebrated 20 years of our presence on University Avenue; the hub of the discovery district. The move not only signified our commitment to meet the increased 11 We Are Augmenting Correlative Cancer Biology demands and evolving needs of our patients, but also encouraged collaboration, innovation, and research, enabling us to continue making progress in conquering cancer. 12 We Are Accelerating Guided Therapeutics Today, we again embrace change as we drive implementation of our space plan, with Marnie Escaf MHA, HBBA 15 We Are Expanding Novel Therapeutics Senior Vice President a focus on redeveloping facilities to improve the patient experience, including patient Executive Lead amenities, access, flow, and wayfinding.
    [Show full text]
  • Stem Cell Strategy by Establishing the Till & Mcculloch Medicines of Tomorrow Innovation Fund
    A Pre-Budget Submission to the House of Commons Standing Committee on Finance To Implement the Canadian Stem Cell Strategy By Establishing The Till & McCulloch Medicines of Tomorrow Innovation Fund James Price President & CEO Canadian Stem Cell Foundation February 9, 2016 EXECUTIVE SUMMARY Stem cells represent the biggest innovation in medicine of the last half century. These cells have the power to cure many diseases for which current medical practice can only provide symptomatic relief and chronic care – a reality that is straining health care systems in Canada and in countries around the globe. Stem cells are a hallmark of Canadian innovation. They were first discovered in Canada and Canada is one of the top three countries in stem cell R&D, with our scientists ranking among the best in the world. Recent investments, such as the Government’s $20-million commitment to establish a cell-manufacturing facility in Toronto and the $114-million Medicine By Design grant for the University of Toronto, will help Canada move forward. However, major commitments by competitor jurisdictions – most notably California, with its investment of $3 billion, and Japan, with an investment of $1 billion in stem cells and regenerative medicine -- challenge Canada’s leadership in this sector of the knowledge economy. Moreover, Canada lacks a national plan to succeed in the coming cell therapy and regenerative medicine boom. The Canadian Stem Cell Strategy -- created in consultation with 150 scientists, medical doctors, leaders from major health charities, industry experts, investors and philanthropists – will: • deliver up to 10 new curative therapies within 10 years; • transform health care and ease the strain on the health system; and • attract private investment and generate 12,000 jobs for Canadians.
    [Show full text]